Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday

Key Points

• Coya Therapeutics is expected to report its Q1 2026 results before the market opens on Tuesday, May 12, with analysts forecasting ($0.39) EPS and about $0.15M in revenue; an earnings call is scheduled for Friday, May 15 at 9:30 AM ET.
• The company missed EPS estimates in the prior quarter (reported ($0.34) vs. consensus ($0.08)), its stock trades around $4.20 with a market cap near $98.5M, and analysts have a consensus rating of “Moderate Buy” with a consensus price target of $16.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Coya Therapeutics to post earnings of ($0.39) per share and revenue of $0.15 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. On average, analysts expect Coya Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Coya Therapeutics Stock Down 1.4%

Shares of COYA stock traded down $0.06 during trading hours on Tuesday, reaching $4.20. 118,426 shares of the stock traded hands, compared to its average volume of 185,052. Coya Therapeutics has a 1-year low of $3.71 and a 1-year high of $7.75. The business has a fifty day moving average price of $4.45 and a 200 day moving average price of $5.17. The firm has a market capitalization of $98.53 million, a PE ratio of -3.31 and a beta of 0.55.

Analyst Ratings Changes

COYA has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Chardan Capital reiterated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Wall Street Zen upgraded shares of Coya Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 18th. D. Boral Capital reaffirmed a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Coya Therapeutics in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the 3rd quarter worth approximately $28,000. CIBC Private Wealth Group LLC bought a new position in Coya Therapeutics in the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics in the 4th quarter worth $66,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Coya Therapeutics in the 2nd quarter worth $119,000. Finally, Millennium Management LLC acquired a new stake in Coya Therapeutics in the 4th quarter worth $121,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.